相关实验视频

Updated: May 7, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.2K

[基于多基因测序的突变的细胞遗传正常急性髓性白血病的基因突变概况和风险分层]

Lei-Ming Cao1, Ming-Yue Liao1, Ya-Lan Zhou1

  • 1Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University,Beijing 100044, China.

Zhongguo shi yan xue ye xue za zhi
|January 1, 2025
PubMed
概括

细胞遗传学上正常的急性髓性白血病 (CN-AML) 和CEBPA-bZIP突变的成年人具有复杂的共同突变. 一种名录模型识别了高风险患者,这些患者可以从全源造血干细胞移植 (allo-HSCT) 中受益.

关键词:
下一代测序;急性髓性白血病;正常型;

更多相关视频

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.1K
Characterizing Mutational Load and Clonal Composition of Human Blood07:58

Characterizing Mutational Load and Clonal Composition of Human Blood

Published on: July 11, 2019

7.3K

相关概念视频

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.1K
Mutations01:39

Mutations

Overview
77.1K